Comparing of OHR Pharmaceutical Inc. (OHRP) and Syros Pharmaceuticals Inc. (NASDAQ:SYRS)

We are comparing OHR Pharmaceutical Inc. (NASDAQ:OHRP) and Syros Pharmaceuticals Inc. (NASDAQ:SYRS) on their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OHR Pharmaceutical Inc. N/A 0.00 13.24M -0.22 0.00
Syros Pharmaceuticals Inc. 1.16M 190.53 59.55M -1.95 0.00

Table 1 highlights OHR Pharmaceutical Inc. and Syros Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 demonstrates the return on assets, net margins and return on equity of OHR Pharmaceutical Inc. and Syros Pharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
OHR Pharmaceutical Inc. 0.00% -62.7% -54.6%
Syros Pharmaceuticals Inc. -5,133.62% -63.8% -51.9%


OHR Pharmaceutical Inc.’s Current Ratio is 5.5 while its Quick Ratio is 5.5. On the competitive side is, Syros Pharmaceuticals Inc. which has a 5.4 Current Ratio and a 5.4 Quick Ratio. OHR Pharmaceutical Inc. is better positioned to pay off short and long-term obligations compared to Syros Pharmaceuticals Inc.

Insider & Institutional Ownership

Institutional investors owned 14.6% of OHR Pharmaceutical Inc. shares and 75.9% of Syros Pharmaceuticals Inc. shares. Insiders owned 8.91% of OHR Pharmaceutical Inc. shares. Comparatively, Syros Pharmaceuticals Inc. has 1.4% of it’s share owned by insiders.


In this table we show the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
OHR Pharmaceutical Inc. -5.33% -32.38% -25.58% -34.41% -90.21% -92.37%
Syros Pharmaceuticals Inc. 18.8% 4.93% -31.5% -35.64% -37.17% -16.86%

For the past year OHR Pharmaceutical Inc. was more bearish than Syros Pharmaceuticals Inc.


On 5 of the 9 factors OHR Pharmaceutical Inc. beats Syros Pharmaceuticals Inc.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing treatments for cancer and immune-mediated diseases, and building a pipeline of gene control medicines. Its lead drug candidates are SY-1425, a selective RARa agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor with potential in a range of solid tumors and blood cancers. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.